drugset / Trial / NCT00631592

GSK1349572 Repeat Dose Escalation and Relative Bioavailability Study

NCT00631592

Phase 1 Completed 44 enrolled ViiV Healthcare
NaSingle-groupDouble-blindTreatment

Summary

This is a repeat dose escalation study of GSK1349572 followed by a relative bioavailability study comparing tablet and suspension formulations in healthy volunteers.

Timeline

Start
2008-02
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Dolutegravir Other / unclassified

Indications

No indication recorded.